JPND Launches €30 Million Call for Multinational Research on Personalised Medicine for Neurodegenerative Diseases
January 9, 2019 - PARIS--(BUSINESS WIRE)
Neurodegenerative diseases are debilitating and still largely untreatable conditions. These diseases are characterised by a large variability in their origins, mechanisms and clinical expression, requesting treatments that will need to take into account all these specificities. Deciphering this variability is one of the biggest challenges in the treatment of neurodegenerative diseases and the way forward is Precision Medicine, supported by highly personalised approaches for the greatest benefit of the patients.
In partnership with the European Commission, JPND is inviting multinational research teams to submit proposals for ambitious, innovative and multidisciplinary collaborative research projects to change the trajectory of these diseases through the development of Precision Medicine approaches.
JPND has chosen to focus in the area of Precision Medicine, which relates to the targeting of specific elements responsible for pathology in a given individual at a particular point in time. It is an emerging approach for disease prevention, diagnosis and treatment that takes into account individual variability in genes, biological/molecular characteristics together with environmental and lifestyle factors.
Proposals submitted under this call must focus on Precision Medicine in one or several of the following research areas:
- Diagnosis (e.g. biomarkers, imaging data, omics approaches, big data analyses).
- Prevention (e.g. biomarkers for studying novel treatments and interventions, co-morbidities, digital technologies, stratification within cohort studies and clinical trials).
- Care (e.g. improvement of social and health care systems, molecular profiling, imaging, lifestyle data).
Proposals must also relate to any or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor Neuron diseases, Hungtington’s disease, Spinocerebellar ataxia and Spinal muscular atrophy.
Pre-proposals must be submitted no later than 15:00h C.E.T. on March 12, 2019.
Illustration Photo: Scientists working on the development of companion diagnostics at QIAGEN's research and development laboratory in in Manchester, UK. (credits: QIAGEN / Flickr Creative Commons Attribution-NonCommercial-NoDerivs 2.0 Generic (CC BY-NC-ND 2.0))